WO2005103690A3 - Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) - Google Patents

Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) Download PDF

Info

Publication number
WO2005103690A3
WO2005103690A3 PCT/EP2005/003821 EP2005003821W WO2005103690A3 WO 2005103690 A3 WO2005103690 A3 WO 2005103690A3 EP 2005003821 W EP2005003821 W EP 2005003821W WO 2005103690 A3 WO2005103690 A3 WO 2005103690A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
crhr2
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/003821
Other languages
French (fr)
Other versions
WO2005103690A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005103690A2 publication Critical patent/WO2005103690A2/en
Publication of WO2005103690A3 publication Critical patent/WO2005103690A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human CRHR2 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, metabolic diseases, hematological disorders, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of CRHR2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/003821 2004-04-24 2005-04-12 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) WO2005103690A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04009782.6 2004-04-24
EP04009782 2004-04-24

Publications (2)

Publication Number Publication Date
WO2005103690A2 WO2005103690A2 (en) 2005-11-03
WO2005103690A3 true WO2005103690A3 (en) 2006-01-19

Family

ID=34979171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003821 WO2005103690A2 (en) 2004-04-24 2005-04-12 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)

Country Status (1)

Country Link
WO (1) WO2005103690A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170153A1 (en) 2016-07-15 2019-01-30 Lilly Co Eli Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236901A (en) * 1988-04-20 1993-08-17 Research Corporation Technologies, Inc. Treatment for irritable bowel syndrome
US20020077468A1 (en) * 1994-06-14 2002-06-20 Lovenberg Timothy W. Corticotropin-releasing factor2 receptors
US20030148958A1 (en) * 2002-01-16 2003-08-07 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2004094419A1 (en) * 2003-04-09 2004-11-04 Sb Pharmco Puerto Rico Inc Condensed n-heterocyclic compounds and their use as crf receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236901A (en) * 1988-04-20 1993-08-17 Research Corporation Technologies, Inc. Treatment for irritable bowel syndrome
US20020077468A1 (en) * 1994-06-14 2002-06-20 Lovenberg Timothy W. Corticotropin-releasing factor2 receptors
US20030148958A1 (en) * 2002-01-16 2003-08-07 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2004094419A1 (en) * 2003-04-09 2004-11-04 Sb Pharmco Puerto Rico Inc Condensed n-heterocyclic compounds and their use as crf receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIEBSCH G ET AL: "DIFFERENTIAL BEHAVIOURAL EFFECTS OF CHRONIC INFUSION OF CRH 1 AND CRH 2 RECEPTOR ANTISENSE OLIGONUCLEOTIDES INTO THE RAT BRAIN", JOURNAL OF PSYCHIATRIC RESEARCH, OXFORD, GB, vol. 33, no. 2, March 1999 (1999-03-01), pages 153 - 163, XP008036948, ISSN: 0022-3956 *

Also Published As

Publication number Publication date
WO2005103690A2 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2006008002A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2004097421A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005106489A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 5 (ccr5)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2006008008A3 (en) Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase